Neurobit Secures Patent for Its AI Sleep Disorder Detection System-Method
Newly patented technology aims to cut diagnostic time and variability while enabling scalable, secure sleep analysis in both clinical and home environments.
Newly patented technology aims to cut diagnostic time and variability while enabling scalable, secure sleep analysis in both clinical and home environments.
The milestone follows a settlement with ResMed, resolving all patent infringement litigation related to Panthera’s mandibular repositioning devices.
The US Patent Trial and Appeals Board has invalidated claims New York University asserted against ResMed related to the company’s patents.
Read MoreThe investigational drug may be able to help patients with Alzheimer’s, Parkinson’s disease, and other central nervous system disorders who often concurrently experience insomnia and/or anxiety, according to the company.
Read MoreThe company says the technology covered by these patents will allow it to offer even more comprehensive solutions to improve the sleep quality of users.
Read MoreThe United States Patent and Trademark Office has denied a Petition for Reexamination concerning a patent covering the active ingredient in Wakix (pitolisant).
Read MoreThe ratio tablet is designed to help consumers fall asleep faster, stay asleep longer, and reduce morning grogginess by dosing in two stages.
Read MoreThe patent describes how the signals recorded from Nox standard respiratory bands can be used to derive information on internal respiratory effort mechanisms.
Read MoreThe patent adds to a portfolio of several issued patents covering ProSomnus’ iterative titration technology in its oral appliance therapy devices.
Read MoreZevra says data from its clinical program for its drug candidate to treat idiopathic hypersomnia will aid the development of treatments for rare sleep disorders through the platform.
Read MoreProsomnus’ oral devices are precision-manufactured with twin-mated posts and digitally milled to be patient-specific, according to the company.
Read MoreSommetrics is advancing activities aimed at obtaining US Food and Drug Administration (FDA) market clearance for its flagship product, aerSleep II, which is targeted for the treatment of obstructive sleep apnea in those unable to use CPAP therapy.
Read More